Cambridge, UK - 24th December 2019
Unaudited Half Year Results
Nuformix (LSE: NFX), the pharmaceutical development Group using cocrystal technology…
News
Cambridge, UK - 25th November 2019
Update and Placing Announcement
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 28th October 2019
Share Listing Anouncement
Following the receipt of Notice of Conversion of Loan Note…
Cambridge, UK - 25th October 2019
Statement re. Share Price Movement
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 10th September 2019
Resignation of Kirk Siderman-Wolter from the Board of Directors
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 9th September 2019
Ebers Tech Strategic Cannabinoid Collaboration Update
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 6th September 2019
Appointment of Dr Muhunthan Thillai to Nuformix Scientific Advisory Board
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 4th September 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 18th July 2019
Final Results for year ended 31 March 2019
The Board of Nuformix plc, (LSE:NFX) is pleased to announce…
Cambridge, UK - 7th June 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 6th June 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 30th May 2019
Positive Results for NXP001 Clinical Trial
Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology…
Cambridge, UK - 24th May 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 24th May 2019
Notice of Loan Conversion
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the…
Cambridge, UK - 22nd May 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 22nd May 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 22nd May 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 15th May 2019
Nuformix Achieves Second NXP001 Development Milestone
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 8th May 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 9th April 2019
Nuformix Enters Strategic Cannabinoid Agreement
Cambridge, UK, 9 April 2019: Nuformix (LSE: NFX), the pharmaceutical…
Cambridge, UK - 5th April 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 22nd March 2019
Nuformix Commences NXP001 Clinical Trial
Cambridge, UK, 22 March 2019: Nuformix (LSE: NFX), the pharmaceutical…
Cambridge, UK - 27th February 2019
Nuformix Announces MHRA Approval to Commence NXP001 Human Pharmacokinetics Studies
Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology…
Cambridge, UK - 20th February 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 20th December 2018
Nuformix Announces Unaudited Half Year Results for the Period Ending 30 September 2018
Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal…
Cambridge, UK - 3rd December 2018
Nuformix Reports Results from Novel Pre-Clinical Trial in IPF for NXP002 Programme
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 27th November 2018
Nuformix Expands Licensing Agreement with Newsummit Biopharma for cancer supportive care product
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 28th September 2018
Director/PDMR Shareholding
The Company was notified on 28 September 2018 that Kirk…
Cambridge, UK - 28th September 2018
Additional New NXP002 Patent Filing
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 19th September 2018
Result of Annual General Meeting
The Annual General Meeting of Nuformix plc was held on…
Cambridge, UK - 14th September 2018
NXP001 Pre-Clinical Milestone Achieved
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 28th August 2018
Renewal of Loan Notes
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 16th August 2018
2018 Annual Financial Report and Notice of Annual General Meeting
The Company announces that the following documents were posted to…
Cambridge, UK - 15th August 2018
Nuformix PLC – Annual General Meeting – Proxy Form
Nuformix PLC – Annual General Meeting – Proxy Form…
Cambridge, UK - 26th July 2018
Final Results for year ended 31 March 2018
The Board of Nuformix plc, (LSE:NFX) is pleased to announce…
Cambridge, UK - 4th July 2018
CEO Interview – Dr Daniel Gooding : Nuformix
Cambridge, UK - 2nd July 2018
Operational Update
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 26th June 2018
Collaboration with St George Street Capital
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 11th May 2018
Nuformix appoints Dr Chris Blackwell as Non-executive Director
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 24th April 2018
Notification Major Interests Shares
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 2nd March 2018
NFX Update re Broker
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 27th February 2018
TR-1: Standard form for notification of major holdings
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 31st January 2018
Positive Results from NXP002 Pilot Study in Lung and Liver Fibrosis
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 15th December 2017
Cocrystal Agreement for NXP001 with Newsummit Biopharma & £2.5m Payment plus Double Digit Royalty on Sales
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 14th December 2017
NFX Advisory Panel
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 6th December 2017
NFX Broker Appt Warrants
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 1st December 2017
Appointment of Broker
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 19th October 2017
Nuformix signs agreement with Quotient Clinical to commence a pilot bioequivalence study for NXP001
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 19th October 2017
Nuformix signs agreement with Quotient Clinical to commence a pilot bioequivalence study for NXP001
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 18th October 2017
NFX on Vox Markets
Since shares commenced their first days trading under…
Cambridge, UK - 17th October 2017
‘Takeover’s healthy side effect’ – Completion of Nuformix’s acquisition by Levrett plc in The Times
The news of the completion of Nuformix’s acquisition…
Cambridge, UK - 16th October 2017
Shakespeare Martineau’s Keith Spedding speaks on Levrett plc’s completed acquisition of Nuformix
Having worked on the original IPO of Levrett,…
Cambridge, UK - 16th October 2017
Nuformix CEO, Dan Gooding on Vox Markets – Elevator Pitch
Nuformix CEO, Dan Gooding, provides a first summary…
Cambridge, UK - 16th October 2017
‘£12m take-over for Cambridge firm speeding up drug discovery’ – Nuformix RTO featured in the Cambridge News
The news of the completion of Nuformix’s acquisition…
Cambridge, UK - 16th October 2017
Nuformix CEO, Dan Gooding, interviewed by Vox Markets’ Justin Waite
As Nuformix shares commence their first days…
Cambridge, UK - 16th October 2017
‘Levrett snaps up Cambridge Pharma Company’ – Nuformix RTO featured on Insider Media
The news of the completion of Nuformix’s acquisition…
Cambridge, UK - 16th October 2017
Notice of Admission to Trading on The Official List and to Trading on the London Stock Exchange’s Market for Regulated Securities
Following a Reverse Takeover on the London Stock Exchange’s market…
Cambridge, UK - 16th October 2017
Notice Of Cancellation Of Admission To Trading On The Official List And To Trading On The London Stock Exchange’s Market For Regulated Securities
Following a Reverse Takeover on the London Stock Exchange’s market…
Cambridge, UK - 13th October 2017
The Company announces that today the name of the Company has been changed from Levrett plc to Nuformix plc.
Levrett, a Company formed to acquire a target company with…
Cambridge, UK - 13th October 2017
GM Results and Completion of Acquisition of Nuformix Limited
Levrett, a Company formed to acquire a target company with…